|
|
癌–睾丸抗原CT23在女性恶性肿瘤(乳腺癌、卵巢癌、子宫内膜癌)诊断价值的探究
|
Abstract:
目的：探讨CT23及其抗体在女性恶性肿瘤(乳腺癌、卵巢癌、子宫内膜癌)辅助诊断中的应用价值。方法：选取卵巢癌患者65例、乳腺癌患者54例、子宫内膜癌患者35例、盆腔良性肿瘤患者21例及健康对照组70例，通过ELISA检测血清中CT23含量及CT23抗体表达水平。结果：肿瘤组患者的CT23和CT23抗体平均含量均高于健康对照组，其中卵巢癌患者组与健康对照组差异具有统计学意义(P < 0.001)。ROC曲线分析显示，CT23对女性肿瘤的诊断价值有限，而CT23抗体可能是乳腺癌或卵巢癌的中度血清标志物。结论：CT23抗体在乳腺癌和卵巢癌的诊断中具有一定的参考价值，但其临床意义仍需进一步研究验证。
Purpose: To explore the application value of CT23 and its antibody in the auxiliary diagnosis of female malignant tumors (breast, ovarian, endometrial). Methods: A total of 65 patients with ovarian cancer, 54 patients with breast cancer, 35 patients with endometrial cancer, 21 patients with benign pelvic tumors, and 70 healthy controls were selected. The levels of CT23 and CT23 antibody in serum were detected using ELISA. Results: The average levels of CT23 and CT23 antibody in the tumor group were higher than those in the healthy control group, with statistically significant differences in the ovarian cancer patient group (P < 0.001). ROC curve analysis showed that CT23 had limited diagnostic value for female tumors, while CT23 antibody might be a moderate serum marker for breast cancer or ovarian cancer. Conclusion: CT23 antibody has certain reference value in the diagnosis of breast cancer and ovarian cancer, but its clinical significance requires further research and verification.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Salmaninejad, A., Zamani, M.R., Pourvahedi, M., Golchehre, Z., Hosseini Bereshneh, A. and Rezaei, N. (2016) Cancer/testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers. Immunological Investigations, 45, 619-640. https://doi.org/10.1080/08820139.2016.1197241 |
| [3] | Gibbs, Z.A. and Whitehurst, A.W. (2018) Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors. Trends in Cancer, 4, 701-712. https://doi.org/10.1016/j.trecan.2018.08.005 |
| [4] | Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., et al. (2021) Cancer/testis Antigens: From Serology to Mrna Cancer Vaccine. Seminars in Cancer Biology, 76, 218-231. https://doi.org/10.1016/j.semcancer.2021.04.016 |
| [5] | Ren, S., Zhang, Z., Li, M., Wang, D., Guo, R., Fang, X., et al. (2023) Cancer Testis Antigen Subfamilies: Attractive Targets for Therapeutic Vaccine (Review). International Journal of Oncology, 62, Article No. 71. https://doi.org/10.3892/ijo.2023.5519 |
| [6] | Nin, D.S. and Deng, L. (2023) Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. Cells, 12, Article 926. https://doi.org/10.3390/cells12060926 |
| [7] | Ono, T., Kurashige, T., Harada, N., Noguchi, Y., Saika, T., Niikawa, N., et al. (2001) Identification of Proacrosin Binding Protein Sp32 Precursor as a Human Cancer/Testis Antigen. Proceedings of the National Academy of Sciences of the United States of America, 98, 3282-3287. https://doi.org/10.1073/pnas.041625098 |
| [8] | Baba, T., Niida, Y., Michikawa, Y., Kashiwabara, S., Kodaira, K., Takenaka, M., et al. (1994) An Acrosomal Protein, Sp32, in Mammalian Sperm Is a Binding Protein Specific for Two Proacrosins and an Acrosin Intermediate. Journal of Biological Chemistry, 269, 10133-10140. https://doi.org/10.1016/s0021-9258(17)37000-x |
| [9] | Kanemori, Y., Ryu, J., Sudo, M., Niida-Araida, Y., Kodaira, K., Takenaka, M., et al. (2013) Two Functional Forms of ACRBP/sp32 Are Produced by Pre-mRNA Alternative Splicing in the Mouse1. Biology of Reproduction, 88, 1-8. https://doi.org/10.1095/biolreprod.112.107425 |
| [10] | Tanphaichitr, N., Kongmanas, K., Kruevaisayawan, H., Saewu, A., Sugeng, C., Fernandes, J., et al. (2015) Remodeling of the Plasma Membrane in Preparation for Sperm-Egg Recognition: Roles of Acrosomal Proteins. Asian Journal of Andrology, 17, 574-582. https://doi.org/10.4103/1008-682x.152817 |
| [11] | Lin, L., Nong, W., Luo, B., Ge, Y., Zeng, X., Li, F., et al. (2021) Cancer‐Testis Antigen ACRBP Expression and Serum Immunoreactivity in Ovarian Cancer: Its Association with Prognosis. Immunity, Inflammation and Disease, 9, 1759-1770. https://doi.org/10.1002/iid3.534 |
| [12] | Li, X., Yan, J., Fan, R., Luo, B., Zhang, Q., Lin, Y., et al. (2017) Serum Immunoreactivity of Cancer/Testis Antigen OY-TES-1 and Its Tissues Expression in Glioma. Oncology Letters, 13, 3080-3086. https://doi.org/10.3892/ol.2017.5799 |
| [13] | Luo, B., Yun, X., Fan, R., et al. (2013) Cancer Testis Antigen OY-TES-1 Expression and Serum Immunogenicity in Colorectal Cancer: Its Relationship to Clinicopathological Parameters. International Journal of Clinical and Experimental Pathology, 6, 2835-2845. |
| [14] | Luo, B., Yun, X., Li, J., Fan, R., Guo, W., Liu, C., et al. (2020) Cancer-Testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Current Medical Science, 40, 719-728. https://doi.org/10.1007/s11596-020-2241-x |
| [15] | 姜丹凤, 朱孟秀, 赵清娟等. 中国女性生殖系统肿瘤发病率和死亡率分析[J]. 现代肿瘤医学, 2023, 31(23): 4426-4431. |
| [16] | 孔艺燕, 应小燕. 复发性卵巢癌治疗的应用进展[J]. 中国妇产科临床杂志, 2023, 24(5): 550-552. |
| [17] | 孙政, 顾振鹏, 丁梦凯, 等. 子宫内膜癌血清标志物的研究进展[J]. 中国当代医药, 2023, 30(4): 34-38, 43. |
| [18] | 王静, 王萍. 卵巢癌肿瘤标志物的早期诊断价值研究新进展. 河北北方学院学报(自然科学版), 2019, 35(12): 60-61 |
| [19] | 郭俊英, 廖沁园. 卵巢癌的分子标志物及靶向治疗研究进展[J]. 世界最新医学信息文摘, 2019, 19(96): 88-89. |
| [20] | 特日格乐, 苏尼尔, 金焰. 卵巢癌分子诊断标记物的研究进展[J]. 国际遗传学杂志, 2014, 37(3): 109-113. |
| [21] | 刘丽, 郝建军, 李勇. CA125、CA199与CEA联合检测对卵巢癌的诊断价值[J]. 系统医学, 2023, 8(11): 168-171. |
| [22] | 杨云波, 冯维, 邹洁洁. 血清HE4、CA125、CEA和CA199联合检测在卵巢良恶性肿瘤中的诊断价值[J]. 现代实用医学, 2021, 33(5): 665-666. |
| [23] | 耿海慧, 曹爱华. 卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J]. 陕西医学杂志, 2022, 51(7): 886-889. |
| [24] | 徐一方, 韩海心, 杨讯. 血清AFP、CEA、CA199、CA125联合HE4检测对卵巢癌的诊断价值分析[J]. 临床研究, 2022, 30(9): 143-145, 152. |
| [25] | 谢长乐, 罗育豪, 黄旭纯, 许镒洧. 血清NY-ESO-1自身抗体在乳腺癌中的诊断价值[J]. 转化医学杂志, 2018, 7(3): 137-139. |
| [26] | Piura, E. and Piura, B. (2011) Autoantibodies to Tailor-Made Panels of Tumor-Associated Antigens in Breast Carcinoma. Journal of Oncology, 2011, Article ID: 982425. https://doi.org/10.1155/2011/982425 |
| [27] | Cui, Z., Chen, Y., Hu, M., Lin, Y., Zhang, S., Kong, L., et al. (2020) Diagnostic and Prognostic Value of the Cancer-Testis Antigen Lactate Dehydrogenase C4 in Breast Cancer. Clinica Chimica Acta, 503, 203-209. https://doi.org/10.1016/j.cca.2019.11.032 |
| [28] | Whitehurst, A.W., Xie, Y., Purinton, S.C., Cappell, K.M., Swanik, J.T., Larson, B., et al. (2010) Tumor Antigen Acrosin Binding Protein Normalizes Mitotic Spindle Function to Promote Cancer Cell Proliferation. Cancer Research, 70, 7652-7661. https://doi.org/10.1158/0008-5472.can-10-0840 |
| [29] | Fu, J., Luo, B., Guo, W.W., et al. (2015) Down-Regulation of Cancer/Testis Antigen OY-TES-1 Attenuates Malignant Behaviors of Hepatocellular Carcinoma Cells in Vitro. International Journal of Clinical and Experimental Pathology, 8, 7786-7797. |
| [30] | Ning, W., Huang, M., Wu, S., Wang, H., Yao, J., Ge, Y., et al. (2021) CT23 Knockdown Attenuating Malignant Behaviors of Hepatocellular Carcinoma Cell Is Associated with Upregulation of Metallothionein 1. Cell Biology International, 45, 1231-1245. https://doi.org/10.1002/cbin.11567 |
